PolyPid Ltd. (PYPD)Healthcare | Biotechnology | Petah Tikva, Israel | NasdaqCM
5.33 USD
-0.02
(-0.374%) ⇩
(July 15, 2026, 11:15 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:49 a.m. EDT
The investment case here is effectively nonexistent due to a catastrophic multi-year decline. The stock has lost 99.2% of its value over the last five years, with every single year showing negative returns. This is not a temporary setback; it is a structural implosion where the market has repeatedly rejected the business model. Fundamentals confirm the doom: the company is burning cash with negative returns on equity and assets, trading at a negative forward P/E because it generates no profit. While the pipeline has some FDA milestones ahead, the balance sheet is fragile, and the stock trades at a premium to book value despite having no earnings power. There is no dividend to cushion the blow, and the options market is screaming 'sell' with heavy put buying and no speculative call interest. Even with a high analyst target price, the math suggests the current price is a value trap rather than a bargain, as the business quality has deteriorated so severely that the market refuses to assign it a higher valuation. Avoid this security entirely. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.034290 |
| MSTL | 0.047705 |
| AutoETS | 0.055348 |
| AutoARIMA | 0.058859 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 1.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.529 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.686 |
| Market Cap | 102,197,832 |
| Forward P/E | -4.25 |
| Beta | 1.40 |
| Website | https://www.polypid.com |
As of July 11, 2026, 3:49 a.m. EDT: Speculators are overwhelmingly bearish, with massive open interest in out-of-the-money puts (100 contracts at $5.00 for November expiration) and zero call volume beyond the immediate term. The call market shows heavy positioning in the money against the strike, while put writers are active, suggesting a strong consensus expectation of further downside or a lack of catalysts to drive a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.41909814 |
| Address1 | 18 Hasivim Street |
| All Time High | 583.5 |
| All Time Low | 2.3 |
| Ask | 6.77 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 270,150 |
| Average Daily Volume3 Month | 144,147 |
| Average Volume | 144,147 |
| Average Volume10Days | 270,150 |
| Beta | 1.4 |
| Bid | 3.86 |
| Bid Size | 2 |
| Book Value | 0.458 |
| City | Petah Tikva |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.33 |
| Current Ratio | 1.782 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.4929 |
| Day Low | 5.2015 |
| Debt To Equity | 26.686 |
| Display Name | PolyPid |
| Earnings Call Timestamp End | 1,778,675,400 |
| Earnings Call Timestamp Start | 1,778,675,400 |
| Earnings Timestamp | 1,778,675,400 |
| Earnings Timestamp End | 1,786,537,800 |
| Earnings Timestamp Start | 1,786,537,800 |
| Ebitda | -31,731,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.963 |
| Enterprise Value | 94,015,320 |
| Eps Current Year | -1.4275 |
| Eps Forward | -1.255 |
| Eps Trailing Twelve Months | -1.74 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.7788 |
| Fifty Day Average Change | 0.5511999 |
| Fifty Day Average Change Percent | 0.11534274 |
| Fifty Two Week Change Percent | 41.909813 |
| Fifty Two Week High | 5.615 |
| Fifty Two Week High Change | -0.28499985 |
| Fifty Two Week High Change Percent | -0.050756875 |
| Fifty Two Week Low | 3.06 |
| Fifty Two Week Low Change | 2.27 |
| Fifty Two Week Low Change Percent | 0.74183005 |
| Fifty Two Week Range | 3.06 - 5.615 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,593,178,200,000 |
| Float Shares | 10,905,065 |
| Forward Eps | -1.255 |
| Forward P E | -4.247012 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21228 |
| Held Percent Institutions | 0.34848 |
| Implied Shares Outstanding | 19,174,078 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-26 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,695,254,400 |
| Last Split Factor | 1:30 |
| Long Business Summary | PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. |
| Long Name | PolyPid Ltd. |
| Market | us_market |
| Market Cap | 102,197,832 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_49223295 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -33,629,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 102,964,798 |
| Number Of Analyst Opinions | 4 |
| Open | 5.38 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 7 4719 5700 |
| Previous Close | 5.35 |
| Price Eps Current Year | -3.7338002 |
| Price Hint | 2 |
| Price To Book | 11.637554 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.548 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.01999998 |
| Regular Market Change Percent | -0.37383142 |
| Regular Market Day High | 5.4929 |
| Regular Market Day Low | 5.2015 |
| Regular Market Day Range | 5.2015 - 5.4929 |
| Regular Market Open | 5.38 |
| Regular Market Previous Close | 5.35 |
| Regular Market Price | 5.33 |
| Regular Market Time | 1,784,128,530 |
| Regular Market Volume | 42,113 |
| Return On Assets | -1.1506801 |
| Return On Equity | -7.58606 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 19,174,078 |
| Shares Percent Shares Out | 0.0044 |
| Shares Short | 84,501 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 138,198 |
| Short Name | PolyPid Ltd. |
| Short Percent Of Float | 0.006 |
| Short Ratio | 0.49 |
| Source Interval | 15 |
| Symbol | PYPD |
| Target High Price | 14.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 12.25 |
| Target Median Price | 13.0 |
| Total Cash | 10,909,000 |
| Total Cash Per Share | 0.569 |
| Total Debt | 2,343,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.27025 |
| Two Hundred Day Average Change | 1.0597501 |
| Two Hundred Day Average Change Percent | 0.24817051 |
| Type Disp | Equity |
| Volume | 42,113 |
| Website | https://www.polypid.com |
| Zip | 4,959,376 |